TOP > 外国特許検索 > CROSSLINKED HYDROPHOBIZED-POLYSACCHARIDE NANOGEL PARTICLES AND MANUFACTURING METHOD THEREFOR

CROSSLINKED HYDROPHOBIZED-POLYSACCHARIDE NANOGEL PARTICLES AND MANUFACTURING METHOD THEREFOR

外国特許コード F150008222
掲載日 2015年3月26日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP059082
国際公開番号 WO 2014157606
国際出願日 平成26年3月28日(2014.3.28)
国際公開日 平成26年10月2日(2014.10.2)
優先権データ
  • 特願2013-072258 (2013.3.29) JP
発明の名称 (英語) CROSSLINKED HYDROPHOBIZED-POLYSACCHARIDE NANOGEL PARTICLES AND MANUFACTURING METHOD THEREFOR
発明の概要(英語) The principal problem addressed by the present invention is the provision of appropriately sized crosslinked hydrophobized-polysaccharide gel particles. To solve said problem, crosslinked hydrophobized-polysaccharide gel particles having particle diameters from 1 to 100 µm are provided.
従来技術、競合技術の概要(英語) BACKGROUND ART
Due to the development of biotechnology, in a cell or a peptide involved in a signaling system, within the cells of the biologically important proteins and plays a role in the cell the nucleic acid delivery to the attempt has been actively performed. These are conventional small molecule compounds from the pharmacological effect cannot be implemented by the pharmaceutical agents can be increased, many outcome is increasing. As a typical insulin and human growth hormone, monoclonal antibodies, various cytokines and the like, in recent years is a complex higher-order structure having a protein or nucleic acid can be isolated and purified relatively easy also for the reason that, of bio-pharmaceuticals is, in a medical field increasingly popular, thought to be important. However, these bio-pharmaceuticals is, generally reduces the stability, decomposition or inactivation in the body to be amenable to from, of very short half-life of the agent as is known. This short half-life, when using the actual maximum efficient in clinical situations in which a problem occurs. At present, many proteins such as cytokines or antibody medicament is, from several days to several weeks to several months or more for each period of administration, must be continuously administered. In many cases, such as infusion treatment methods are performed by injection, patient's quality of life (quality of life, QOL) cannot be said to be high, the distal end of the next generation of bio-pharmaceuticals in medicine is using, by a suitable carrier, in an appropriate location, the desired concentration and time pattern development of regenerative medicine and drug delivery system can deliver been desired earnestly.
On the other hand, in recent years, the field of material science and nanotechnology has generated a new materials than is applied to regenerative medicine and drug delivery attempt has been actively performed. The inventors of the present invention in the case of the polysaccharide mainly constituted by a physically cross-linked nano-gel, have great promise as a carrier protein can be enclosed medicament revealed have shown. By previous studies, nano gel molecular chaperones, cancer immunotherapy clinical levels, intracellular introduction, nasal type such as a vaccine to be used as an important material in the currently known.
Existing work by the inventors of the present invention (patent document 1, non-patent document 1, 2) in, in order to increase the application range of the nano-gel, nano-gel a gel cross-linking points in the preparation of (nano-gel cross-linked gel) attempted. Specifically, the conventional cholesteryl group-introduced pullulan modified with acryloyl groups, the polymerizable nanoparticles having gel was prepared. This polymerizable nano gel, polyethylene glycol is attached to a thiol group at an end by reacting, nano gel crosslinked to form a gel. The nano gel cross-linked gel, encapsulating a protein internal nano gel and has a sustained release is characterized, in particular of regenerative medicine as scaffolding material for many results (non-patent document 2) are enhanced.
Non-patent document 3-7 obtained by the prior art such as nano-gel cross-linked gel, particles or smaller than the particle size of about 100 nm, greater than or equal to the number of large particles either mm, with the size of a micrometer range from a sub-micron nano-gel cross-linked gel that has not been obtained. In the order of magnitude of about 100 nm in a particle of the containment vessel or limited by the claims, is not able to adjust the rate of sustained release, of a size larger than the number of mm nano gel cross-linked gel surgical methods of administration to a body to the surface of the embedded or limited by the joining means. The crosslinking agent without using the nano-gel nano-gel to each other by cross-linking a cross-linked gel was not able to be prepared.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • AKIYOSHI, Kazunari
  • TAHARA, Yoshiro
  • MUKAI, Sadaatsu
  • SAWADA, Shinichi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close